Physician profile
Christopher C Canale
NPI 1598952145
$4,086.03
in general payments reported to CMS, 2019-2025
25 companies · $615 in 2025
The $615 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $361 · 2020: $234 · 2021: $1,137 · 2022: $614 · 2023: $595 · 2024: $530 · 2025: $615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,740.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,739.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,697.17 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Janssen Biotech, INC. | $883.42 | 2019-2025 | Tremfya, Stelara |
| Lucid Diagnostics INC. | $358.36 | 2021-2022 | |
| Pfizer INC. | $314.08 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $202.26 | 2019-2024 | Entyvio |
| Genzyme Corporation | $83.58 | 2023-2024 | |
| Celgene Corporation | $68.73 | 2022-2023 | Zeposia |
| Madrigal Pharmaceuticals | $64.50 | 2024-2025 | Resmetirom, Rezdiffra |
| Ardelyx, INC. | $63.74 | 2024-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $63.37 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $49.52 | 2022 | |
| Organon LLC | $44.72 | 2021-2024 | |
| Qol Medical, LLC | $31.34 | 2019-2024 | Sucraid |
| Janssen Scientific Affairs, LLC | $26.45 | 2019 | |
| Lilly USA, LLC | $21.74 | 2024 | Omvoh |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $21.00 | 2023 | Compliance Endokit |
| Merit Medical Systems INC | $20.25 | 2025 | Esophyx |
| Gilead Sciences, INC. | $16.70 | 2024 | |
| Amag Pharmaceuticals, INC. | $15.35 | 2019 | |
| Novo Nordisk INC | $14.79 | 2025 | Wegovy |
| Redhill Biopharma INC. | $13.39 | 2021 | |
| Alfasigma USA, INC. | $11.57 | 2020 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$14,973.95 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Canale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.